Pancreatic ductal adenocarcinoma (PDAC) is the most common histologic subtype of pancreatic cancer, arising from ductal epithelium and associated with poor prognosis.
Incyte has started the phase 3 Dawn-03 trial of INCB161734 plus chemotherapy in first-line KRAS G12D-mutant pancreatic cancer. The move comes while the phase 1 study remains halted in four European countries after pneumonitis cases, including one grade 5 event.
Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 303 trial testing daraxonrasib as first-line therapy for metastatic pancreatic cancer. The company also expects top-line data from its Phase 3 RASolute 302 trial in second-line pancreatic cancer in the first half of 2026. Both trials are evaluating the oral RAS(ON) inhibitor in pancreatic ductal adenocarcinoma, a highly lethal cancer with significant unmet medical need.
Elicio Therapeutics granted inducement stock options to new employees, with one grant of 1,600 options at $12.16 per share and another of 30,300 options at $8.59 per share. The clinical-stage biotech company is developing novel immunotherapies targeting mKRAS-positive cancers, with its ELI-002 program showing promising Phase 1 results including 16.3-month median recurrence-free survival.
A new four-marker blood test detects pancreatic cancer with 91.9% accuracy across all stages and 87.5% accuracy for early-stage disease. The test combines two newly identified proteins with existing biomarkers and can differentiate cancer from non-cancerous conditions. While promising for pancreatic cancer, most cancers still cannot be reliably diagnosed with blood tests alone.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
Xenetic Biosciences reported a net loss of $2.7 million for 2025 while advancing its DNase-based cancer therapy toward clinical trials, ending the year with $7.9 million in cash. Xeris Biopharma will announce its 2025 financial results on March 2, 2026.
The FDA is accelerating its review of daraxonrasib, a targeted therapy for pancreatic cancer, under a new pilot program that could reduce approval time from 10-12 months to one to two months.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
Researchers develop ultra-sensitive CAR-T cells targeting CD70 for solid tumors and KRASG12V/HLA-A*02:01-specific CAR-T cells for cancers with KRAS mutations, demonstrating efficacy in preclinical models.
Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589205 |
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT07562152 |
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
RECRUITING | PHASE3 |
| NCT07483554 |
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors |
NOT_YET_RECRUITING | PHASE2 |
| NCT07432633 |
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications |
RECRUITING | PHASE1/PHASE2 |
| NCT07328607 |
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy |
RECRUITING | NA |
| NCT07324096 |
A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer |
RECRUITING | NA |
| NCT07284277 |
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) |
RECRUITING | PHASE1/PHASE2 |
| NCT07261631 |
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors |
RECRUITING | PHASE1 |
| NCT07252076 |
PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa |
RECRUITING | |
| NCT07232810 |
Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer |
RECRUITING | NA |
